Related references
Note: Only part of the references are listed.The inhibitory receptor CD94/NKG2A on CD8+ tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE/β2m overexpression
Juliette Eugene et al.
MODERN PATHOLOGY (2020)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
A phase II study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair-proficient (MMR-p) advanced colorectal cancer
Mark Yarchoan et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603).
Shota Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer
Michael A. Morse et al.
ONCOLOGIST (2019)
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
Davide Ciardiello et al.
CANCER TREATMENT REVIEWS (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer.
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.
Eiji Shinozaki et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
ENCORE 601: A phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer.
Nilofer Saba Azad et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
LBA37_PRNeoadjuvant ipilimumab plus nivolumab in early stage colon cancer
M Chalabi et al.
ANNALS OF ONCOLOGY (2018)
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition
David A. Fabrizio et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)
KEYNOTE-177: Phase 3, open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC).
Luis A. Diaz et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications
Jessica Roelands et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE. Mutation
Jun Gong et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
Bert H. O'Neil et al.
PLOS ONE (2017)
Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials
Manni Wang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer.
Safi Shanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency
Remi Bourdais et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Phase 2 study of pembrolizumab in combination with azacitidine in subjects with metastatic colorectal cancer.
James J. Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Colorectal cancer statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership
Enrique Chajon et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
The evolving role. of microsatellite instability in colorectal cancer: A review
Fabio Gelsomino et al.
CANCER TREATMENT REVIEWS (2016)
Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy
Etienne Becht et al.
CLINICAL CANCER RESEARCH (2016)
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
Bernhard Mlecnik et al.
IMMUNITY (2016)
KEYNOTE-164: Phase II study of pembrolizumab (MK-3475) for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma.
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A panoply of errors: polymerase proofreading domain mutations in cancer
Emily Rayner et al.
NATURE REVIEWS CANCER (2016)
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study
Enric Domingo et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2015)
Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
The consensus molecular subtypes of colorectal cancer
Justin Guinney et al.
NATURE MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Leisha A. Emens et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model
Lotfi Abou-Elkacem et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer
Arnaud D. Roth et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial
Takayuki Yoshino et al.
LANCET ONCOLOGY (2012)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
Combining immunotherapy and targeted therapies in cancer treatment
Matthew Vanneman et al.
NATURE REVIEWS CANCER (2012)
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies
Michael Dechant et al.
CANCER RESEARCH (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer
Alberto Malesci et al.
CLINICAL CANCER RESEARCH (2007)
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer:: The Gruppo Oncologico Nord Ovest
Alfredo Falcone et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Diagnostic approach and management of Lynch syndrome (Hereditary Nonpolyposis Colorectal Carcinoma):: A guide for clinicians
Yvonne M. C. Hendriks et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2006)
Screening for the Lynch syndrome (Hereditary nonpolyposis colorectal cancer).
H Hampel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Systematic review of microsatellite instability and colorectal cancer prognosis
S Popat et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
JE Ohm et al.
BLOOD (2003)
Phenotype of microsatellite unstable colorectal carcinomas - Well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability
JK Greenson et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2003)
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
A de Gramont et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
